Welcome to our dedicated page for Codexis news (Ticker: CDXS), a resource for investors and traders seeking the latest updates and insights on Codexis stock.
Codexis, Inc. develops enzyme-based solutions for therapeutics manufacturing, using its CodeEvolver technology to discover and improve high-performance enzymes. Company news commonly covers financial results, guidance, cash-runway commentary, and business updates tied to small molecule pharmaceutical biocatalysis, nucleic acid synthesis, and the ECO Synthesis manufacturing platform for enzymatic RNAi and siRNA production.
Recurring developments include partner and evaluation agreements, technology-transfer activity, quality-system and manufacturing-suite updates, conference data on ECO Synthesis capabilities such as phosphorothioate stereochemistry and ligation efficiency, and portfolio updates for enzymes used in branded pharmaceutical products.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Codexis (NASDAQ: CDXS) announced it will release its financial results for Q1 2023 on May 4, 2023, after market closure. The company will not hold a conference call following this release. Codexis specializes in enzyme engineering, utilizing its CodeEvolver® technology platform to develop high-performance enzymes for various applications, including pharmaceuticals and biotherapeutics. Their technology aims to enhance manufacturing efficiency, reduce energy consumption, and improve therapeutic efficacy. The company's innovations address challenges in small molecule production, nucleic acid synthesis, and genomic sequencing.
Codexis (NASDAQ: CDXS) will host a workshop at the TIDES USA annual meeting on May 7, 2023, focusing on enzymatic solutions for RNA-based therapeutics manufacturing. As RNA therapeutics, particularly mRNA vaccines and siRNA candidates, gain momentum, challenges in production quality, quantity, and economics persist. Codexis aims to showcase how its engineered enzymes can address these issues, potentially enhancing scalability and sustainability in the manufacturing process.
The presentation, titled 'Engineered Enzymes to Overcome Scalability and Sustainability Challenges of Nucleic Acid Therapeutics Manufacturing,' will take place from 12:30 PM to 1:30 PM PT at Manchester Grand Hyatt in San Diego, CA. An archive will be available to registered attendees on the TIDES USA platform and Codexis' website.